Broader population could benefit from Novartis spinal muscular atrophy treatment

Broader population could benefit from Novartis spinal muscular atrophy treatment

Submitted by admin on January 13, 2025 - 5:39pm
Source: 
Clinical Trials Arena
News Tags: 
Novartis
SMA
OAV101 IT
Headline: 
Broader population could benefit from Novartis spinal muscular atrophy treatment
snippet: 

Positive results from its Phase III STEER study mean Novartis could boost sales of its OAV101 IT drug for spinal muscular atrophy.

Do Not Allow Advertisers to Use My Personal information